Boehringer Ingelheim said recently that it has completed a €105 million expansion of its facilities in Dortmund and Ingelheim, Germany to increase manufacturing capacity for its Respimat soft mist inhaler. The company said that the expansion has been completed in time to support its launch of a next generation Respimat in Europe this year.
The new Respimat is reusable and allows for easy change out of the cartridges, BI said, making the inhaler more sustainable. The new device also has a larger dose indicator and easier dose preparation procedures.
According to the company, a new assembly line for the improved Respimat in Dortmund accounts for €78 million of the investment, and the remainder was spent on a new packaging line in Ingelheim.
BI Country Manager Sabine Nikolaus said, “The volume of the investment and further development of Respimat demonstrate Boehringer Ingelheim’s long-term commitment to combating serious respiratory diseases. This also underscores our commitment to Germany as a production location.”
Read the Boehringer Ingelheim press release.
